blissonmoon,
If you read further the poster who mentioned PFE and DNA recanted and said he was "kidding" (not funny, I know). There is a poison pill from way back that makes a hostile takeover highly unlikely. Based on the apparent view of the current management they have always had a propensity to go it alone in hopes of reaping all the rewards (either a very deep belief in the value of the drug or a stubborness. I like the first story best). Partnership is a possibility on some of the indications IMHO.
The $22 target a few years ago was before a 1 for 4 reverse split and prior to the failure of INS-1 in diabetes trials. INS 1 was Insmed's original drug candidate. Somatokine(now named IPlex) was acquired when Insmed purchased Celtrix a few years ago. This stock has been in the low $.30 range in October 2002 just after the failure of INS-1.
One might question whether I have been here too long, huh? Always believed in the science, have received one hell of an education, and made a little money along the way.
GLTA! Slacker